Evidence map›Paper›PMID 34640396›Full record

ArticleJournal of clinical medicine2021

Different Impact of Beta-Blockers on Long-Term Mortality in Heart Failure Patients with and without Chronic Obstructive Pulmonary Disease.

Satoshi Higuchi, Takashi Kohno, Shun Kohsaka, Yasuyuki Shiraishi, Makoto Takei, Ayumi Goda, Satoshi Shoji, Yuji Nagatomo, Tsutomu Yoshikawa

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Appraisal of β-Blocker Use in Patients with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Satoshi HiguchiDepartment of Emergency and General Medicine, Kyorin University School of Medicine, Tokyo 181-8611, Japan.ORCID 0000-0002-7914-8256
Takashi KohnoDepartment of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo 181-8611, Japan.
Shun KohsakaDepartment of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID 0000-0003-3779-2972
Yasuyuki ShiraishiDepartment of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID 0000-0001-8788-1186
Makoto TakeiDepartment of Cardiology, Saiseikai Central Hospital, Tokyo 108-0073, Japan.
Ayumi GodaDepartment of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo 181-8611, Japan.
Satoshi ShojiDepartment of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID 0000-0002-2223-7215
Yuji NagatomoDepartment of Cardiology, National Defense Medical College, Tokorozawa 359-8513, Japan.ORCID 0000-0002-3430-4614
Tsutomu YoshikawaDepartment of Cardiology, Sakakibara Heart Institute, Tokyo 183-0003, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The administration of beta-blockers is challenging and their efficacy is unclear in heart failure (HF) patients with chronic obstructive pulmonary disease (COPD). This study aimed to investigate the association of beta-blockers with mortality in such patients. This multicenter observational cohort study included hospitalized HF patients with a left ventricular ejection fraction <50% and evaluated them retrospectively. COPD was diagnosed based on medical records and/or the clinical judgment of each investigator. The study endpoints were two-year all-cause, cardiac, and non-cardiac mortality. This study included 83 patients with COPD and 1760 patients without. Two-year all-cause, cardiac, and non-cardiac mortality were observed in 315 (17%), 149 (8%), and 166 (9%) patients, respectively. Beta-blockers were associated with lower all-cause mortality regardless of COPD (COPD: hazard ratio [HR] 0.39, 95% CI 0.16-0.98,

Indexed as

beta-blockerchronic obstructive pulmonary diseaseheart failureheart failure with mid-range ejection fractionheart failure with reduced ejection fraction

Identifiers

PMID34640396
PMCPMC8509631

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.